Manipal Health Enterprises, India's largest multi-specialty hospital group by bed capacity (49 hospitals, 13,037 beds), closed its ₹9,275 crore IPO on July 31, 2026 — subscribed ~4.9x overall. Of the total raise, ₹8,000 crore is a fresh issue and only ₹1,275 crore is an OFS (offer for sale by existing shareholders).
Here is the first thing a CFO reads in any IPO prospectus: not the price band, not the GMP — the fresh-issue-vs-OFS split.
A quick gloss: a fresh issue means the company itself gets the cash. An OFS (offer for sale) means existing investors or promoters are selling their shares and pocketing the proceeds — the company sees ₹0 of it.
In Manipal's case, ₹8,000 crore out of ₹9,275 crore is a fresh issue. That's ~86% of the raise going directly into the business. The prospectus is explicit: most of it is earmarked for debt repayment at Manipal Hospitals Private Limited and part for acquiring the remaining stake in Sahyadri Hospitals.
A CFO would ask: why is a company with ₹10,335 crore in revenue carrying enough debt that it needs a public market event to clean up its balance sheet? The answer is probably Sahyadri — acquisitions are expensive and leave leverage behind.
Now the uncomfortable number. FY26 revenue grew ~25%. PAT (profit after tax) fell ~15%. Higher employee costs, finance charges, and depreciation from the Sahyadri deal compressed the bottom line. A CFO reads that as an integration cost story, not a broken business — but it explains why the IPO is priced at ~85x earnings against a peer average of ~70x. You're paying for the post-debt-cleanup earnings power, not the current one.
The module here is Fundraising — every rupee in an IPO has a destination, and the split tells you who's actually getting paid.
📚 Learn the concept: Fundraising
Source: https://www.ipoguru.in/ipo-review/manipal-health-enterprises-ipo
▶ Play the 90-second CFO game All daily posts